Reports

Drug name	NICE TAs	Comments
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome TA256 - Atrial fibrillation (stroke prevention) - Rivaroxaban TA261 - Venous thromboembolism (treatment and long-term secondary prevention) - Rivaroxaban TA287 - Pulmonary embolism and recurrent venous thromboembolism TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Amber - specialist initation following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants Amber - specialist initation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD Amber - specialist initiation for preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Use following Hip and Knee surgery- full course of treatment supplied on discharge.
Rivastigmine capsules	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA
Rivastigmine patches	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA
Roflumilast (Daxas)	TA461 - Roflumilast for treating chronic obstructive pulmonary disease	To be use in line with NICE. Supported with a RICaD
Romiplostim injection	TA221 - Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Romosozumab (Evenity®)	TA791 - Romosozumab for treating severe osteoporosis
Rucaparib (Rubraca®)	TA611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer NICE TA 1007 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer NICE TA 1055 Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy	https://www.nice.org.uk/guidance/ta1055?UNLID=4609200102025625122051
Ruxolitinib (Jakavi®)	TA289 - Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis TA921: Ruxolitinib for treating polycythaemia vera NICE TA 1054 Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over
Sacituzumab govitecan	TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports